Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499087 | 0.91 | CYP19A1 (0.42) | CYP19A1MTNR1AMTNR1BCHRNB2CHRNA7 | |
| SCHEMBL4490551 | 0.87 | MTNR1A (0.38) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL4498277 | 0.85 | MTNR1A (0.61) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL4498964 | 0.85 | MTNR1A (0.42) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL4492602 | 0.84 | MTNR1A (0.49) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL1379087 | 0.83 | DAO (0.41) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL4499201 | 0.80 | MEN1 (0.38) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL4505261 | 0.79 | MTNR1A (0.52) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL8230415 | 0.79 | CYP19A1 (0.57) | CYP19A1 | |
| SCHEMBL4510000 | 0.77 | MTNR1A (0.52) | CYP19A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | CYP19A1 1030/4885MTNR1A 454/4885MTNR1B 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.